Recently, Sanofi-Aventis, the world's third-largest pharmaceuticals group, announced in Beijing that it will implement a plan to expand its R&D scale in China, expand its research and development organization in Shanghai, launch the newly-built Beijing Biometrics Center, and cooperate with the Shanghai Life Science Institute of Chinese Academy of Sciences. The institute has signed research cooperation agreements to jointly explore innovative drugs for neurological diseases, diabetes and cancer treatment. On the same day, Sanofi-Aventis held a signing ceremony for a strategic cooperation agreement with the Shanghai Institute of Life Sciences, Chinese Academy of Sciences. Marek, senior vice president of global research and development at Sanofi-Aventis, announced the establishment of the first Chinese research fund to train and honor outstanding people who conduct research in the fields of structural chemistry, biology, and pharmacology. Wu Jiarui, vice president of the Shanghai Institute of Life Sciences, Chinese Academy of Sciences, stated that the cooperation agreement plans to cooperate in the research and development of advanced innovative drugs. This will enhance the level of Chinese medicine research and development, and promote the rapid transformation of basic research results into therapeutic drugs to benefit patients. Jiang Ningjun, vice president of global R&D and president of China's R&D, Sanofi-Aventis, said that he will fully support scientific research to meet the medical needs of patients in China and around the world in order to improve the international competitiveness of drug innovation in China. In another development, Sanofi-Aventis also launched a complete vaccine development project in China. Sanofi-Aventis is increasing its expansion of the Chinese vaccine market. In 2012, the company's influenza vaccine production plant in Shenzhen will be put into operation. By then, Sinon will sell 25 million seasonal influenza vaccines annually in China. Stamping parts: The most used in hardware processing refers to the molds for steel/non-ferrous metals and other plates at room temperature, which are formed into a specified shape by the pressure required for processing by a press. Automobile shock absorbers are mainly used to suppress the shock of the spring and the impact from the road surface when the spring rebounds after shock absorption. When passing on uneven roads, although the shock-absorbing spring can filter the vibration of the road, the spring itself will reciprocate, and the car shock absorber is used to suppress the jump of this spring. If the shock absorber is too soft, the body will jump up and down. If the shock absorber is too hard, it will bring too much resistance and prevent the spring from working properly. In the process of modifying the suspension system, the hard shock absorber should be matched with the hard spring, and the hardness of the spring is closely related to the weight of the car. Therefore, heavier cars generally use harder automotive shock absorber stamping parts. A device connected to the vibration-inducing crankshaft to counteract the torsional vibration of the crankshaft (that is, the phenomenon that the crankshaft is twisted by the impact of the ignition of the cylinder) Stamping parts bracket,Shock Absorber Parts Ningbo Huilexin Technology Co.LTD , https://www.oemshockabsorbers.com
The property market in Beijing, which was once very strong, has also started to decline. In September, the housing price in Beijing fell by 0.2%...
According to Marek, the Group's China Clinical Research Center, established in Shanghai in 2005, conducts various clinical trials with the most stringent quality standards and participates in various compound research projects including Laureate, Rimonabassa, Polyvita, and Rabies Vaccine. The Beijing Biostatistics Center, which was recently completed, will be fully operational by the end of this year. According to reports, the center can provide clinical trial research design, data management and statistical analysis for the world. In cooperation with the Tianjin Institute of Hematology, Chinese Academy of Medical Sciences, we have succeeded in isolating potential cancer stem cells and entering antibody research on cancer stem cells, which is expected to be transformed into drugs for the treatment of leukemia.
Pharmaceutical giant Sanofi-Aventis plans to expand its research and development in China